用天然激动剂TRLW-2准孕妇X受体中的一个独特的结合口袋,可以改善小鼠性结肠炎
Shangrui Rao1, Yi Mei2, Lingyan Shi1
1Department of Colorectal and Anal Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Frontiers in pharmacology
|December 29, 2025
概括
研究人员确定了一个新的孕妇X受体 (PXR) 结合部位 (口袋1-5) 和一种天然化合物,TRLW-2 (catechin),用于治疗性结肠炎 (UC). 在临床前模型中,TRLW-2显示出抗炎和治疗作用.
科学领域:
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
- 计算化学的计算化学
背景情况:
- 对于性结肠炎 (UC) 的孕妇X受体 (PXR) 激动剂的治疗开发受限于 kanonical 结合体结合口袋的选择性差.
- 针对性UC疗法需要在PXR上建立一个新的,增强选择性的结合部位.
研究的目的:
- 确定PXR.上一个新的,增强选择性的结合位点.
- 为了发现一个自然的连接体,针对这个部位治疗性结肠炎 (UC).
主要方法:
- 计算方法 (SiteMap,Fpocket,Prank,CASTpFold) 确定了一个新的PXR绑定口袋 (口袋1-5).
- 在对6,058种天然化合物的基于结构的虚拟选中,TRLW-2 (catechin) 被确定为主要候选物.
- 在体外和体内试验评估了TRLW-2在小鼠结肠炎模型中的有效性.
主要成果:
- TRLW-2显示出对1-5口袋的高度亲和力,通过分子动力学和突变发生验证.
- TRLW-2作为一种强大的PXR激活剂,调高排毒酶和扩散标记物的作用.
- 在体内,TRLW-2显著改善了结肠炎症状和结肠损伤.
结论:
- 1-5口袋是PXR的一个选择性增强站点.
- 天然产品TRLW-2有效地准了这个口袋,显示出抗炎和粘膜愈合特性.
- 这一战略为UC的精密治疗提供了一个有前途的方法.
更多相关视频
10:51Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
Published on: November 15, 2013
13.1K
08:02Visualization of Estrogen Receptors in Colons of Mice with TNBS-Induced Crohn's Disease using Immunofluorescence
Published on: March 12, 2020
7.0K
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
416
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
416
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.0K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.0K
